Skip to main content

PDSB

Stock
Health Care
Biotechnology

Performance overview

PDSB Price
Price Chart

Forward-looking statistics

Beta
1.48
Risk
87.37%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Company info

SectorHealth Care
IndustryBiotechnology
Employees25
Market cap$106.9M

Fundamentals

Enterprise value$39.8M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity84.79

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.94
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$900K
Avg trading volume (10 day)$580K
Put-call ratio

Macro factor sensitivity

Growth-1.0
Credit+9.3
Liquidity+0.5
Inflation-6.6
Commodities-1.1
Interest Rates-1.7

Valuation

Dividend yield0.00%
PEG Ratio-0.94
Price to sales
P/E Ratio-0.94
Enterprise Value to Revenue
Price to book2.70

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day
Ex. dividend day

News

Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for PDS Biotechnology (PDSB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Investment Research (November 20, 2024)
PDS Biotechnology Gains On FDA Fast Track Designation For Lead Candidate

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PDS Biotechnology's (NASDAQ: PDSB) lead drug candidate PDS0101 in combination with KEYTRUDA (pembrolizumab) for the treatment of patients with recurrent or metastatic HPV16-positive head and neck cancer.

Benzinga (June 2, 2022)
Top Stocks To Short As Dow Surges From Boeing Gains

As the virus spreads, if you're looking to bet against the market or hedge, our deep learning algorithms paired with out Artificial Intelligence ('AI') data has some Top Shorts named for you today.

Forbes (June 29, 2020)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free